HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer celebrates UK Viagra switch

This article was originally published in OTC Bulletin & The Rose Sheet

Executive Summary

Men in the UK will soon have OTC access to Pfizer’s blockbuster erectiledysfunction treatment Viagra after an application to switch the sildenafil-based product was given the green light.

You may also be interested in...



OTC Marketing Awards 2019 Winners Announced – GSK Crowned Company Of The Year, Pfizer’s Viagra Takes Best Brand

GSK, Pfizer, HRA Pharma and Mentholatum all enjoyed a particularly fruitful evening at the OTC Marketing Awards 2019. J&J, P&G and RB were also among the winners at a celebration of the best and brightest in the UK consumer health market. 

How China Inc. Aims To Take Over Cell Therapy Dominance

Just three years after its founding, Chinese cell therapy developer IASO Bio already has two assets in clinical development and the Nanjing firm has recently attracted $60m in financing. In an exclusive interview, its R&D head told Scrip that speed and partnerships are propelling Chinese developers on a trajectory to quickly catch up with the west in the emerging cell-therapy arena.

QUOTED. 14 August 2020. Jonathan Walker.

Updated guidance from England’s National Institute for Health and Care Excellence says two neurostimulation systems for treatment-resistant depression and epilepsy should only be used under special conditions. See what LivaNova’s VP of difficult-to-treat depression, Jonathan Walker, said about it here.

Topics

UsernamePublicRestriction

Register

LL1131561

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel